AzTrials
AzTrials

Pulmonary EmbolismNCT00117169

Multi-Detector Spiral Computed Tomography Alone Versus Combined Strategy With Lower Limb Compression Ultrasonography in Outpatients Suspected of Pulmonary Embolism

A study testing multi-detector helical computed tomography in people with Pulmonary Embolism, run by University Hospital, Geneva at 1 site in Switzerland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The main hypothesis for this study is that the diagnostic approach of pulmonary embolism (PE) by evaluation of clinical probability, D-dimer test dosage and multi-detector helical computed tomography (hCT) is as safe as the classical "approach" using clinical probability, D-dimer test, lower limb compression… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pulmonary Embolism
What is being tested?
multi-detector helical computed tomography
Type of treatment
Surgery or procedure
How many people
1,500 participants
Where
1 siteSwitzerland
Study dates
Jan 2005to Oct 2006
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All outpatients admitted to the emergency ward for suspected pulmonary embolism, defined as acute onset of new or worsening shortness of breath or chest pain without another obvious etiology, will be included in the study, provided they meet all other criteria and they have signed an informed consent form.

Who cannot join

  • PE suspicion raised more than 24 hours after admission to the hospital
  • Absence of informed consent
  • Life expectancy of less than 3 months
  • Geographic inaccessibility for follow-up
  • Pregnancy
  • Patients anticoagulated for a disease other than venous thromboembolism (for instance, atrial fibrillation)
  • Patients allergic to contrast medium
  • Impaired renal function (creatinine clearance less than 30 ml/min, as calculated by the Cockroft formula)

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • Geneva University Hospital

    Geneva, Canton of Geneva, 1205

Other trials in Switzerland

About this study

Official title: Multi-Detector Spiral Computed Tomography Alone Versus Combined Strategy With Lower Limb Compression Ultrasonography in Outpatients Suspected of Pulmonary Embolism: A Randomised Non-Inferiority Trial [CTEP4]

The main hypothesis for this study is that the diagnostic approach of pulmonary embolism (PE) by evaluation of clinical probability, D-dimer test dosage and multi-detector helical computed tomography (hCT) is as safe as the classical "approach" using clinical probability, D-dimer test, lower limb compression ultrasonography and multi-detector helical computed tomography.

The second hypothesis involves evaluating the role of searching distal, i.e. infrapopliteal, deep venous thromboses (DVTs) in the diagnostic approach of pulmonary embolism.

Read the detailed description

Suspected pulmonary embolism [PE] is a frequent clinical problem and remains a diagnostic challenge. The diagnostic approach of PE relies on sequential diagnostic tests, such as plasma D-dimer measurement, lower limb compression ultrasonography, ventilation-perfusion lung scan or helical computed tomography [hCT] and pulmonary angiography. In addition, the diagnostic workup is usually stratified according to the clinical probability of pulmonary embolism.

First-generation hCTs were based on a single-detector technique and had a limited 70% sensitivity. Moreover, in two recent outcome studies, a proximal deep venous thrombosis diagnosed by lower limb compression ultrasonography was found in 15% of patients with a normal single-detector hCT. However, in management studies, the association of a normal lower limb compression ultrasonography and a normal single-detector hCT has been proved safe to rule out PE in patients with a non-high clinical probability, with a less than 2% rate of thromboembolic events during a 3-month follow-up in patients left untreated based on that combination. Hence, lower limb compression ultrasonography must be combined with a single-detector CT to safely rule out pulmonary embolism.

More recently, the multi-detector hCT has become widely available. These new scanners allow one to improve image definition and to diminish slice thickness without increasing acquisition time and, hence, to better visualize the segmental and sub-segmental pulmonary arteries. In a recent study [CTEPm], the investigators evaluated the performances of a multi-detector hCT. The rate of false negative results, assessed by the rate of patients with proximal DVT on ultrasonography and a negative hCT, was much lower using the multi-detector CT [0.9%, 95% confidence interval: 0.3-3.3%] than with the single-detector technique [15%]. This raises the possibility that hCT might be used as a single test to rule out PE in patients with an elevated D-dimer level. Indeed, ELISA plasma D-dimer measurement in patients with a non-high clinical probability of PE remains a logical first step since it safely rules out PE in approximately 30% of patients. Such a strategy should now be validated in a prospective randomised outcome study to compare its safety and cost-effectiveness with that of a previously validated strategy combining D-dimer, lower limb compression ultrasonography and hCT.

Therefore, the investigators plan to compare the efficacy and cost-effectiveness of two distinct diagnostic strategies for suspected pulmonary embolism in emergency center patents in a non-inferiority trial. The strategies are: 1) an algorithm based on clinical assessment, D-dimer and multi-detector hCT (DD-hCT); and 2) a previously validated strategy that includes lower limb compression (DD-US-hCT). The main outcome will be the rate of thromboembolic events during a formal 3-month follow-up in patients not anticoagulated on the basis of a PE ruled out by the diagnostic criteria in each study arm. A secondary outcome will be the costs of diagnosis in each study arm, including the costs of suspected and/or confirmed thromboembolic events during follow-up.

In addition, the investigators aim to prospectively and pragmatically validate the revised Geneva score for assessing the clinical probability of PE by using it in the sequential diagnostic work-up for PE. Classification performances of this score will be assessed by checking its capacity to discriminate between patients having a low, intermediate, or high probability of PE.

Finally, in a nested study, the investigators aim to compare the clinical usefulness of a complete lower limb compression ultrasonography versus a classical "4-points ultrasonography" (ultrasonography of the proximal veins) in the patients from the ultrasound arm of the study (DD-US-hCT). Indeed, preliminary data indicate that complete ultrasound detects a DVT in a higher proportion of patients with PE than proximal ultrasound (US) and, hence, has the potential for further limiting the requirement for chest imaging in patients with suspected PE. Because finding a distal DVT is of uncertain clinical significance, such a finding will not be reported to the clinicians in charge of the patient and those patients will undergo a helical CT and be treated (or not) according to the CT result. Outcome measurements will be the number of patients in whom hCT could have been avoided by ruling in the diagnosis of PE in the presence of a distal DVT (proportion of patients with both distal DVT on ultrasonography and pulmonary embolism on multi-detector hCT) and the number of patients who would have been unduly anticoagulated if considering the presence of a distal DVT in the complete compression ultrasonography (proportion of patients with distal DVT on ultrasonography, but without pulmonary embolism on multi-detector hCT, and without a thromboembolic event during the 3 month follow-up).

Being tested
multi-detector helical computed tomography
Keywords
Pulmonary embolism, multi-detector helical computed tomography clinical probability, clinical score
Medical subject headings
Pulmonary Embolism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • multi-detector helical computed tomographyProcedure or surgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The primary outcome variable will be the number of thromboembolic events in the 3-month follow-up period in each group.

Secondary outcomes (4)
  1. Costs incurred in each study arm. (Costs will be directly measured and will represent direct costs, not charges. Measurements will include all costs due to diagnosis of PE, including the costs associated with the length of stay in the emergency ward)

  2. Classification performances of the revised Geneva standardised clinical score, as assessed by its capacity to distinguish patients having low, intermediate and high probability of PE

  3. Proportion of patients in whom hCT could have been avoided by using the presence of a distal DVT to rule in the diagnosis of PE (proportion of patients with both distal DVT on ultrasonography and PE on multi-detector hCT)

  4. Proportion of patients with distal DVT on ultrasonography but without pulmonary embolism on multi-detector hCT and without thromboembolic event during the 3 months follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Jul 2005 (estimated)
  2. Study startJan 2005
  3. Study completionOct 2006

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Enrolment
1,500 participants
IDs, dates and publications
ClinicalTrials.gov ID
NCT00117169
Sponsor's protocol ID
CT-EP4
Other IDs
FNRS, Grant No 3200B0-105988
Status last verified
Oct 2012
First submitted
30 Jun 2005
Last updated
15 Oct 2012
Results posted
No

Publications

  • Perrier A, Roy PM, Sanchez O, Le Gal G, Meyer G, Gourdier AL, Furber A, Revel MP, Howarth N, Davido A, Bounameaux H. Multidetector-row computed tomography in suspected pulmonary embolism. N Engl J Med. 2005 Apr 28;352(17):1760-8. doi: 10.1056/NEJMoa042905.

    PubMed 15858185
  • Bertoletti L, Le Gal G, Aujesky D, Sanchez O, Roy PM, Verschuren F, Bounameaux H, Perrier A, Righini M. Prognostic value of the Geneva prediction rule in patients with pulmonary embolism. Thromb Res. 2013 Jul;132(1):32-6. doi: 10.1016/j.thromres.2013.05.001. Epub 2013 May 26.

    PubMed 23714176
  • Righini M, Le Gal G, Aujesky D, Roy PM, Sanchez O, Verschuren F, Kossovsky M, Bressollette L, Meyer G, Perrier A, Bounameaux H. Complete venous ultrasound in outpatients with suspected pulmonary embolism. J Thromb Haemost. 2009 Mar;7(3):406-12. doi: 10.1111/j.1538-7836.2008.03264.x. Epub 2008 Dec 20.

    PubMed 19143927
  • Vuilleumier N, Le Gal G, Verschuren F, Perrier A, Bounameaux H, Turck N, Sanchez JC, Mensi N, Perneger T, Hochstrasser D, Righini M. Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study. J Thromb Haemost. 2009 Mar;7(3):391-8. doi: 10.1111/j.1538-7836.2008.03260.x.

    PubMed 19087222
  • Righini M, Le Gal G, Aujesky D, Roy PM, Sanchez O, Verschuren F, Rutschmann O, Nonent M, Cornuz J, Thys F, Le Manach CP, Revel MP, Poletti PA, Meyer G, Mottier D, Perneger T, Bounameaux H, Perrier A. Diagnosis of pulmonary embolism by multidetector CT alone or combined with venous ultrasonography of the leg: a randomised non-inferiority trial. Lancet. 2008 Apr 19;371(9621):1343-52. doi: 10.1016/S0140-6736(08)60594-2.

    PubMed 18424324

Questions about this trial

What is this clinical trial studying?

A study testing multi-detector helical computed tomography in people with Pulmonary Embolism, run by University Hospital, Geneva at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Oct 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The primary outcome variable will be the number of thromboembolic events in the 3-month follow-up period in each group.. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00117169, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2012; AzTrials last refreshed its copy on 31 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in